COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04380688

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

2020-05-08

Completed

RCT

Randomized

Parallel

Open label

multi-center

Treatment

inclusion criteria: ability to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations) men and women ≥18 years of age at the time of signing the informed consent form confirmed infection with sars-cov-2 confirmed per world health organization criteria (including positive rt-pcr nucleic acid test) covid-19 pneumonia (documented radiographically) requiring hospitalization and oxygen saturation <94% on room air or requires supplemental oxygen able to swallow pills willing to follow contraception guidelines

respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. known medical resuscitation within 14 days of randomization pregnant or breast feeding suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

2

AstraZeneca

18

130

United States

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

62

Number of Participants With Adverse Events and Serious Adverse Events;Percentage of Participants Alive and Free of Respiratory Failure at Day 28

None

Phase 2

[{"arm_notes": "", "treatment_id": 12, "treatment_name": "Acalabrutinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]